Maine CDC Information
- Health Topics A-Z
- Conferences & Events
- Data and Reports
- Maine CDC Rules
- Public Health Training
- State Health Improvement Plan
- About Us
District Public Health
- Local Health Officers
- Local Public Health Districts
- Public Health Emergency Preparedness
- Statewide Coordinating Council
Information for Health Care Providers
Maine CDC Health Advisory
February 7, 2022
COVID-19 Pre-exposure Prophylaxis for Patients with Moderate/Severe Immunocompromise
This health alert provides an update on patient eligibility for EVUSHELD, a long-acting monoclonal antibody that is available under U.S. Food and Drug Administration Emergency Use Authorization for pre-exposure prophylaxis to prevent COVID-19 infection in persons with moderate to severe immunocompromise.
Vaccination for COVID-19 remains the best protection against infection, hospitalization, and death. However, individuals with immunocompromising conditions, or taking certain immunocompromising medications, may be less likely to mount an appropriate immune response to COVID-19 vaccination, leaving them at elevated risk for COVID-19 infection, hospitalization, and death. Many such persons are already at elevated risk for severe disease from COVID-19 due to their existing health conditions. Pre-exposure prophylaxis is now available for certain individuals who have been vaccinated against COVID-19 but remain highly susceptible to this infection and subsequent severe disease.
